HER2-Targeted Therapy in NSCLC
Improving Outcomes for Patients With Advanced NSCLC Through the Optimal Integration of HER2-Targeted Antibody–Drug Conjugate Therapy

Released: October 25, 2023

Lyudmila Bazhenova
Lyudmila Bazhenova, MD
Karen Reckamp
Karen Reckamp, MD, MS

Activity

Progress
1
Course Completed